ACUTE LYMPHOBLASTIC LEUKEMIA

Acute Lymphoblastic Leukemia is a malignant neoplasm of the blood and bone marrow, characterized by the uncontrolled proliferation of immature **lymphoblasts** (B or T cells) that suppress normal hematopoiesis.

1. Diagnostic Aspects and Pathogenesis

Category	Key Technical Data	Relevance for AI (Input/Output)
Histological Definition	> **Accumulation of lymphoid blasts** in the bone marrow of total nucleated cells.	**Input:** Percentage of blasts (diagnostic threshold criterion).
Immunophenotypic Markers	**B-Lineage (most common):** TdT, CD19, CD79a, CD22. Often positive for CD10 (CALLA).	**RAG Output:** Specific subtype classification (e.g., Pre-B vs. T).
	T-Lineage: TdT, CD3 (cytoplasmic or surface), CD2, CD5, CD7.	**Input:** CD expression profile.
Genetic Risk Factors	**Recurrent Chromosomal Abnormalities:** /BCR-ABL (Philadelphia Chromosome, high risk), /KMT2A-AFF1 (very high risk), trisomies (e.g., Trisomy 4, 10, 17, standard risk).	**Input:** FISH/Cytogenetics results (for risk stratification).
Clinical Presentation	Symptoms due to **marrow failure**: Anemia (fatigue, pallor), Neutropenia (recurrent infections), Thrombocytopenia (bleeding/bruising).	**RAG Output:** Correlation between hematological picture and symptoms.
ICD-10 Code	C91.0 (Acute Lymphoblastic Leukemia).	**Output:** Coding and billing.

---

2. Diagnostic Categories and Progression Stages for AI

The AI application must be capable of classifying disease progression based on cytological, immunophenotypic, and molecular parameters. The requested categories are mapped here to standard hematological diagnostic concepts.

2.1. Benign (Non-cancerous, healthy cells)

This category defines a state where ALL is not present.

Diagnostic Parameter	Value/Description for AI	Clinical Relevance
Bone Marrow Blasts	of nucleated cells (normal range).	Exclusion of leukemia.
Bone Marrow	**Normal trilineage hematopoiesis** (balanced presence of erythroid, myeloid, and megakaryocytic precursors).	Functional, non-suppressed cells.
Genetic Profile	**Absence of ALL-specific gene fusions** (e.g., BCR-ABL1 negative).	Low probability of developing ALL in the short term.

2.2. Pre (Pre-stage abnormal cells) / Myelodysplastic Syndromes (MDS) or Pre-Leukemic States

Although ALL is acute, the concept of a "pre-stage" can be mapped to conditions with **mild clonal abnormalities** that do not yet meet ALL criteria, or conditions like Myelodysplastic Syndromes (MDS) in pediatric/young adult settings.

Diagnostic Parameter	Value/Description for AI	Clinical Relevance
Bone Marrow Blasts	of nucleated cells. This falls within the MDS range (specifically RAEB-2, which is high risk for transformation).	**High Risk (Pre-Leukemia):** Requires close surveillance and preventative intervention if parameters warrant.
Dysplasia	**Cytopenia** with dysplasia in one or more cell lines.	Indicates impaired marrow function and a clonal defect.
Genetic Abnormalities	Detection of **Clonal Hematopoiesis of Indeterminate Potential (CHIP)** mutations or MDS-related abnormalities.	Signaling a potential *driver* for progression.

2.3. Early (Early stages of leukemia) / ALL Diagnosis

This category represents the time of formal ALL diagnosis, when the WHO criteria are met.

Diagnostic Parameter	Value/Description for AI	Clinical Relevance
Bone Marrow Blasts (Threshold Criterion)	of nucleated cells.	**Confirmed Diagnosis:** Immediate initiation of induction therapy.
Immunophenotype	**Lineage determined** (B or T) with full expression of immaturity markers (e.g., TdT+).	Essential classification for the therapeutic protocol.
Presence of T(9;22)	Positive detection of the **BCR-ABL1** fusion gene.	**RAG Input for Therapy:** Indicates the need for Tyrosine Kinase Inhibitors (TKIs) like Imatinib, alongside chemotherapy.

Diagnostic Parameter	Value/Description for AI	Clinical Relevance
Leukemic Burden	High White Blood Cell (WBC) count at presentation (is often associated with worse prognosis).	Early risk stratification.

2.4. Pro (Advanced leukemia cells) / Refractory ALL or Very High-Risk ALL

This category refers to an established ALL condition that is **resistant to initial treatment (refractory)** or presents extremely poor prognostic risk factors.

Diagnostic Parameter	Value/Description for AI	Clinical Relevance
Minimal Residual Disease (MRD)	**Positive MRD** (> or leukemic cells) after Induction or Consolidation Phase.	**Key Prognostic Indicator:** Predicts relapse. AI should suggest therapeutic escalation.
Clinical Refractoriness	**Failure to achieve Complete Remission (CR)** after Induction Chemotherapy (e.g., bone marrow blasts on Day 28).	**Urgency:** Need for salvage therapeutic lines (e.g., Blinatumomab, Tisagenlecleucel/CAR-T).
Genetic-Molecular Abnormalities	Detection of mutations associated with **resistance** (e.g., TKI-resistant mutations in BCR-ABL1).	**RAG Output:** Selection of second/third-generation inhibitors.
Early Relapse	Return of the disease **within 18 months** of initial diagnosis.	Sign of poor prognosis and need for Allogeneic Hematopoietic Stem Cell Transplant (HSCT).

1. Authoritative Medical / Academic Documentation for ALL

(All sources are widely accepted in hematology, oncology, and pathology training.)

1.1. NCCN Guidelines – Acute Lymphoblastic Leukemia

National Comprehensive Cancer Network (NCCN Clinical Practice Guidelines).
Covers:

- Diagnostic workup
- Immunophenotyping (B-ALL vs T-ALL)
- Cytogenetics & molecular markers (Ph+, MLL-r, iAMP21)
- Risk stratification

- Minimal residual disease (MRD)
- Treatment by phase (induction, consolidation, maintenance)
- Relapse / refractory pathways

This is the **single most important document** for ALL clinical management.

1.2. WHO Classification of Tumours (5th Edition): Haematolymphoid Tumours

Covers ALL in the context of:

- **Normal hematopoiesis (benign cells)**
- **Early / precursor lymphoid neoplasms**
- **B-lymphoblastic and T-lymphoblastic leukemia** (your "early," "pre," and "pro" stages)
- Immunophenotypic markers (CD10, CD19, CD20, TdT, CD34, CD7, CD3, etc.)
- Morphology, genetics, and diagnostic thresholds

Essential for mapping your categories to recognized hematological stages.

1.3. Harrison's Principles of Internal Medicine — Chapter on Leukemias

Provides:

- ALL epidemiology
- Clinical presentation
- Lab findings
- Bone marrow morphology
- Flow cytometry interpretation
- Treatment overview
- Prognostic factors (age, WBC count, cytogenetics)

Good for your AI to understand the *clinical reasoning* steps.

1.4. Robbins & Cotran Pathologic Basis of Disease

Provides the **pathological foundation**, including:

- Difference between benign hematopoiesis vs leukemic blasts
- How genetic mutations cause transformation

- How blasts accumulate → “early” → “pre-leukemic” → “pro-leukemic” progression
- Bone marrow changes across stages
- Organ infiltration patterns (liver, spleen, CNS)

Strong foundation for biological mechanisms.

1.5. UpToDate – “Clinical features and diagnosis of acute lymphoblastic leukemia”

Sections you should extract:

- Blast morphology & cytochemistry
- Peripheral smear interpretation
- MRD technology
- Differential diagnosis: aplastic anemia, infectious lymphocytosis
- Laboratory abnormalities (TLS, cytopenias, LDH)

Excellent for diagnostic algorithms your RAG agent may reference.

1.6. Blood (ASH Journal) Review Articles

Examples include:

- “Biology and treatment of acute lymphoblastic leukemia”
- “Minimal residual disease in ALL – implications for therapy”
- “Genomic landscape of ALL”

These provide cutting-edge mechanistic insights and terminology.

1.7. WHO / ICC Leukemia Progression Framework

For mapping your categories:

Your Category	Hematology / WHO Equivalent	Description
Benign	Normal hematopoiesis	Mature lymphocytes; no blasts
Early	*Early lymphoid precursor lesions*	Mild abnormality; <5% blasts
Pre	*Precursor lymphoid neoplasm / pre-leukemic state*	Clonal abnormal precursors; risk of conversion; 5–19% blasts
Pro	**Acute Lymphoblastic Leukemia**	≥20% blasts in bone marrow or blood

Acute Lymphoblastic Leukemia (ALL): Comprehensive Overview for Clinicians

Acute Lymphoblastic Leukemia (ALL), also known as acute lymphocytic leukemia, is a heterogeneous malignant neoplasm of immature lymphoid precursors (lymphoblasts) of B-cell (B-ALL, ~75–85%) or T-cell (T-ALL, ~15–25%) lineage. It is the most common childhood cancer (peak 2–5 years) but occurs across all ages, with a second peak in adults >50 years. Overall incidence: ~1.7/100,000 annually; pediatric cure rates >90%, adult 5-year OS ~40–50% (improving with targeted therapies). Driven by chromosomal translocations, aneuploidy, and mutations disrupting lymphoid development.

Pathophysiology: Arrest at early stages of differentiation leads to uncontrolled proliferation of lymphoblasts replacing normal hematopoiesis → pancytopenia. Extramedullary involvement common (CNS, testes, lymph nodes, liver/spleen).

Clinical Presentation: Rapid onset (days–weeks): Fatigue/anemia, infections/neutropenia, bleeding/thrombocytopenia, bone pain, hepatosplenomegaly, lymphadenopathy, CNS symptoms (headache, cranial nerve palsies), testicular enlargement (males). Hyperleukocytosis (>100 × 10^9/L) risks leukostasis/tumor lysis syndrome (TLS).

Risk Factors: Genetic syndromes (Down syndrome ↑20–30× risk), prior chemotherapy/radiation, EBV (some T-ALL), familial predisposition (rare).

Diagnostic Categories in AI Microscopy Datasets (C-NMC/ALL Challenge Style)

The categories requested (benign, early, pre, pro) refer to **visual morphology of lymphoblasts in peripheral blood/bone marrow smears** used in public AI training datasets (e.g., the 2019 C-NMC dataset with ~3,256 images). These are **not formal WHO/ICC/ELN clinical subtypes** but empirical staging of B-ALL blast maturation based on nuclear/cytoplasmic features observed under light microscopy (often in pediatric B-ALL cases). They represent a continuum of blast immaturity:

Category	Description (Morphologic Features)	Clinical Correlation	Frequency in Datasets	Key Differential
Benign (Non-cancerous, healthy cells)	Normal mature lymphocytes or reactive lymphocytosis; small round nucleus, condensed chromatin, scant cytoplasm, no nucleoli or blasts. May include hematogones (normal B-precursors in children: high N/C ratio but regular chromatin, no atypia).	No leukemia; reactive (infection, autoimmune) or recovering marrow.	Control group	Reactive lymphocytosis, hematogones
Early (Early stages of leukemia)	Large blasts with **immature/indistinct nucleoli**, high N/C ratio, fine chromatin, scant basophilic cytoplasm, irregular nuclear contours. Corresponds to most primitive blasts (closest to L1/L2 FAB but with minimal maturation signs).	Earliest detectable malignant blasts; often high-risk genetics.	~20–30% malignant images	Primitive B-ALL blasts
Pre (Pre-stage abnormal	Blasts with **prominent/single large central nucleolus**, moderate cytoplasm, slightly	Intermediate maturation; typical of	~40–50% malignant images	Transitional blasts

Category	Description (Morphologic Features)	Clinical Correlation	Frequency in Datasets	Key Differential
cells; Pre-B blasts)	coarser chromatin than early. Represents partial maturation arrest (pre-B immunophenotype common).	common B-ALL.		
Pro (Advanced leukemia cells; Pro-B blasts)	Blasts with **multiple prominent nucleoli**, abundant cytoplasm, vacuoles common, coarser chromatin. More "mature-appearing" but still malignant.	More differentiated but aggressive; often pro-B subtype.	~20–30% malignant images	Mature-appearing B-ALL or Burkitt-like

These categories are **dataset-specific** and used for training CNNs to detect ALL from blood smears (sensitivity/specificity >95% in top models). In real practice, **any malignant blast >20% in marrow = ALL** regardless of "early/pre/pro" appearance; morphology alone cannot reliably subclassify.

Formal Clinical Classification (WHO 5th ed. 2022 / ICC 2022 / ELN 2024)

Lineage	WHO 5th (2022) / ICC Subtype	Key Genetic/Molecular Features	Frequency	Prognostic Implications (Adults)
B-ALL	B-lymphoblastic leukemia/lymphoma, NOS	No defining genetic abnormality	~10–15%	Variable; often standard risk
	B-ALL with BCR::ABL1 (Ph+)	t(9;22) or variants	25% adults, <5% peds	Poor without TKI; improved with ponatinib + immunotherapy
	B-ALL with BCR::ABL1-like (Ph-like)	CRLF2, JAK2, ABL-class rearrangements	20–30% adults, 10–15% peds	Poor; JAK inhibitors (ruxolitinib trials)
	B-ALL with KMT2A rearrangement	t(v;11q23.3)	5–10% (80% infants)	Very poor in infants
	B-ALL with TCF3::PBX1	t(1;19)	~5%	Favorable with intensive therapy
	B-ALL with iAMP21	Intrachromosomal amplification of chr 21	~2%	Poor (treated as high-risk)
	B-ALL with hypodiploidy (<44 chr)	Low hypodiploidy/near-haploidy	~2–5%	Very poor
	B-ALL with hyperdiploidy (>50 chr)	Trisomies 4,10,17 common	~25% peds, rare adults	Excellent (peds)
	B-ALL with ETV6::RUNX1	t(12;21)	~25% peds	Excellent

Lineage	WHO 5th (2022) / ICC Subtype	Key Genetic/Molecular Features	Frequency	Prognostic Implications (Adults)
	B-ALL with DUX4 rearrangement (new in ICC)	NUP214::ABL1, MEF2D, ZNF384 fusions also recognized	Variable	Often favorable (DUX4)
T-ALL	T-lymphoblastic leukemia/lymphoma	NOTCH1/FBXW7 mutations (>70%), CDKN2A loss	15–25%	Intermediate; early T-precursor (ETP-ALL) worst
	Early T-cell precursor (ETP-ALL) subtype	Stem-cell/myeloid gene expression, DNMT3A/FLT3/IDH1-2 mut	~10–15% of T-ALL	Poor; consider myeloid-directed Rx
MPAL	Mixed phenotype acute leukemia (rare)	B/myeloid, T/myeloid, etc.	<5%	Poor; ALL- or AML-based Rx

Diagnostic Workup (ELN 2024 / NCCN 2025)

1. **Morphology + Immunophenotype (mandatory):** ≥20% lymphoblasts in BM/PB; flow cytometry for lineage (cCD79a/TdT/CD19 for B; cCD3 for T).
2. **Cytogenetics/FISH:** Karyotype + targeted FISH (BCR::ABL1, KMT2A, etc.).
3. **Molecular:** NGS panel (TP53, IKZF1, JAK-STAT for Ph-like); RT-PCR for fusions.
4. **MRD:** Flow or qPCR at end-induction (threshold <0.01% = best prognosis).
5. **CNS Evaluation:** LP with cytospin/flow at diagnosis.

Risk Stratification (Adults, ELN/NCCN 2025)

Risk Group	Features
Favorable	Hyperdiploidy, ETV6::RUNX1, low MRD
Intermediate	Ph-like without high-risk, T-ALL (non-ETP)
High/Very High	Ph+, KMT2A-r, hypodiploid, TP53 mut, high MRD, ETP-ALL

Management Overview (NCCN 2025 / ELN 2024)

- **Pediatric-inspired multiagent chemo** for AYA/adults <65 (induction → consolidation → maintenance 2–3 yrs).
- **TKI + chemo/immunotherapy** for Ph+ (ponatinib preferred).
- **Blinatumomab/inotuzumab** for CD22+/CD19+ relapsed.
- **CAR-T (tisagenlecleucel/brexucabtagene)** for R/R.
- **Allogeneic HCT** in high-risk/CR1 or R/R.
- **CNS prophylaxis** mandatory (intrathecal MTX ± cranial RT).

Supportive Care: TLS prophylaxis, infection prophylaxis (PCP, mold-active azole), growth factors, transfusion support.

Minimal/Measurable Residual Disease (MRD) Testing in Acute Lymphoblastic Leukemia (ALL)

MRD is the strongest independent prognostic factor in both pediatric and adult ALL. It refers to the small number of leukemic cells that persist during/after treatment but are undetectable by conventional morphology (<5% blasts).

Detection of ≥0.01% (10^{-4}) leukemic cells after induction or consolidation is associated with significantly higher relapse risk and is now used to guide risk stratification, intensification/de-intensification, and indication for allogeneic transplant.

Current Thresholds (2025 ELN/NCCN/ICC Consensus)

Time Point	MRD Negativity Definition	Clinical Impact (Adults)
End of induction (≈ day 28–35)	<0.01% (10^{-4})	Best prognosis; often allows de-escalation in peds-inspired protocols
End of consolidation (≈ week 12–16)	<0.01%	Most powerful time point; drives HCT decision in adults
Any time point	≥0.01%	High risk → consider blinatumomab, inotuzumab, CAR-T, or HCT

Methods for MRD Assessment (Standardized & Harmonized 2025)

Method	Sensitivity	Sample Required	Applicability	Advantages	Limitations
Multicolor Flow Cytometry (MFC)	10^{-4} to 10^{-5}	Bone marrow (preferred) or peripheral blood (less sensitive)	~95% of patients (leukemia-associated immunophenotype, LAIP)	Fast (hours), widely available, quantitative, no patient-specific setup	Requires fresh sample, operator-dependent, lower sensitivity in switched lineage or antigen loss
Real-time quantitative PCR (qPCR)	10^{-4} to 10^{-6}	Bone marrow	70–90% (Ig/TCR rearrangements most common; BCR::ABL1 for Ph+)	Extremely sensitive, standardized (EuroMRD group)	Needs patient-specific primers (2–3 months setup for Ig/TCR), not applicable in ~10% (oligoclonality)
Next-Generation Sequencing (NGS)	10^{-6}	Bone marrow	>98% (tracks Ig/TCR or fusion transcripts)	Highest sensitivity, universal applicability, captures clonal evolution	Longer turnaround (weeks), higher cost, not yet universally reimbursed
Digital-droplet PCR (ddPCR)	10^{-5} to 10^{-6}	Bone marrow or blood	Especially useful for BCR::ABL1, KMT2A, etc.	Absolute quantification, no standard curve needed	Limited targets compared to NGS

Current international consensus (AIEOP-BFM, COG, St. Jude, UKALL, PONAL, GMALL, GRAALL, MD Anderson, etc.):

- Use NGS or flow for first-line MRD in clinical trials and most centers.
- qPCR still gold standard for Ph+ ALL (BCR::ABL1 transcripts reported as % on International Scale).

Practical MRD Testing Algorithm (Adults 2025)

1. **At Diagnosis**
    - Collect bone marrow for baseline immunophenotyping (LAIP), Ig/TCR sequencing (for NGS/qPCR), and molecular genetics.
2. **Time Point 1: End of Induction (TP1, day +28–35)**
    - Preferred method: Flow or NGS
    - If MRD ≥0.1% → high risk (proceed to blina/inotuzumab or HCT planning)
3. **Time Point 2: End of Consolidation (TP2, week 12–16)**
    - Mandatory in all protocols
    - MRD <0.01% + favorable genetics → chemotherapy only
    - MRD ≥0.01% → consider change of therapy (immunotherapy or allo-HCT in CR1)
4. **Later Time Points**
    - Every 3–6 months during maintenance in high-risk patients or trials.

Interpretation & Impact on Therapy (2025 Guidelines)

MRD Status (at end-consolidation)	Pediatric Protocols (e.g., AIEOP-BFM 2020)	Adult Protocols (e.g., GMALL 08/2013 update, US Intergroup)
MRD-negative (<0.01%)	Standard-risk arm, reduced intensity possible	Chemotherapy ± blinatumomab maintenance (no HCT in CR1)
MRD-positive ≥0.01%	High-risk arm, intensification, HCT in CR1	Blinatumomab cycles → re-assess MRD → HCT if still positive or high-risk genetics

Special Situations

- **Ph+ ALL**: Use qPCR for BCR::ABL1 every 3 months; aim for major molecular response (MMR = ≤0.1%) and deeper (MR4.0–MR4.5).
- **Relapsed ALL**: MRD negativity pre-CAR-T or pre-HCT strongly predicts long-term remission.
- **Peripheral blood MRD**: Acceptable for Ph+ (correlates well), emerging for NGS in some subtypes.

Key References (2025)

- ELN MRD Working Party guidelines (Blood 2024)
- ICC 2022 classification (requires MRD assessment)
- NCCN ALL Guidelines v2.2025
- EuroMRD/NGS harmonization papers (Leukemia 2023–2025)

Bottom line for clinicians/AI integration: MRD <0.01% at the end of consolidation is the single most important factor determining cure without transplant in modern ALL therapy. Always use standardized, sensitive ($\geq 10^{-4}$), quantitative methods and report exact level and technique used.

Minimal/Measurable Residual Disease (MRD) in Relapsed Acute Lymphoblastic Leukemia (ALL) – 2025 Update

In relapsed/refractory (R/R) ALL, MRD has evolved from a prognostic marker to a **critical decision-making tool** for salvage therapy selection, response evaluation, and pre-transplant

optimization. Achieving MRD negativity (typically <0.01%) before or after salvage therapy is the strongest predictor of long-term survival, often more important than the number of prior lines or relapse timing.

Key Prognostic Impact of MRD in Relapsed ALL

MRD Status	Context	3–5 Year OS / EFS	Key References (2024–2025)
MRD <0.01% before allo-HCT	Any relapse (early or late)	50–70%	EBMT/ALL-HCT 2023, CIBMTR 2025
MRD ≥0.01% before allo-HCT	Despite salvage therapy	15–30%	Same
MRD-negative after blinatumomab	First salvage, CD19+	60–80% (if consolidated with HCT)	TOWER follow-up, GMMG trials
MRD-negative after inotuzumab	First salvage, CD22+	~50–60%	INO-VATE long-term
MRD-negative after CAR-T (any construct)	R/R after ≥2 lines	50–60% at 3–5 y (tisagenlecleucel, brexucabtagene)	ELIANA, ZUMA-3 updates 2025
Persistent MRD+ after CAR-T	Post-infusion	<20% long-term survival	Multiple real-world registries

Timing and Interpretation of MRD Assessment in Relapsed Setting

Time Point	Recommended Method	Threshold for "Response"	Clinical Action if MRD+
At relapse (before salvage)	Flow or NGS	—	Guides choice: blina/ino if isolated extramedullary or low burden
After salvage immunotherapy (blinatumomab, inotuzumab) – usually week 4–6	Flow (preferred) or NGS	<0.01%	Proceed to consolidation (HCT or CAR-T)
Post-CAR-T (day +28 is standard)	NGS or high-sensitivity flow (10^{-6})	<0.01% (any detectable MRD predicts relapse)	Consider pre-emptive therapy (e.g., second CAR-T, DLI, clinical trial)
Pre-allogeneic HCT	NGS mandatory (most sensitive)	<0.01%	If ≥0.01% → additional cycles of blina/ino or clinical trial before HCT

Current Guidelines (NCCN 2025, ELN 2024, EBMT 2025)

- **All patients with relapsed ALL must have MRD assessment** (preferably NGS ≥10^{-6}) before proceeding to allogeneic HCT.
- **Blinatumomab or inotuzumab** should be continued or repeated until MRD <0.01% (or maximum tolerated cycles) before HCT whenever possible.
- **CAR-T recipients**: MRD negativity at day +28 strongly correlates with durable remission; persistent MRD → high risk of CD19-negative relapse.

- **Post-HCT MRD monitoring**: Monthly NGS or ddPCR for first 6–12 months in high-risk patients → pre-emptive DLI or hypomethylating agents + blinatumomab if MRD re-emerges.

Emerging Strategies for MRD-Positive Relapsed Disease (2025)

Scenario	Approach
MRD+ after blinatumomab	Switch to inotuzumab → re-assess → CAR-T or HCT
MRD+ after inotuzumab	Blinatumomab → CAR-T
MRD+ after CD19 CAR-T	CD22-directed therapy (inotuzumab or CD22 CAR-T trials) or bispecifics (CD19/CD22)
Persistent low-level MRD post-HCT	Donor lymphocyte infusion (DLI), blinatumomab, or azacitidine + venetoclax combinations (investigational)

Practical Take-Home Points for Clinicians (November 2025)

1. **Never transplant an MRD-positive patient without attempting further debulking** if clinically feasible — survival difference is dramatic.
2. **NGS is now preferred over flow** in the relapse setting because of higher sensitivity (10^{-6}) and ability to detect clonal evolution/antigen loss.
3. Achieving MRD <0.01% at any point in the relapsed journey (especially pre-HCT or post-CAR-T) is the single best predictor of long-term leukemia-free survival.
4. MRD-guided sequential therapy (blina → ino → CAR-T → HCT) has pushed 3-year OS in multiply relapsed adults from <10% (historical) to 30–50% in recent prospective trials.

MRD is no longer just prognostic in relapsed ALL — it is now the central therapeutic target driving personalized salvage strategies.

Minimal/Measurable Residual Disease (MRD) in Relapsed Acute Myeloid Leukemia (AML) – 2025 Update

In AML, MRD has become a cornerstone of decision-making in the relapsed/refractory (R/R) setting. While its prognostic role is well established in first-line therapy, its use in relapse has matured dramatically with the approval of highly effective lower-intensity regimens (e.g., venetoclax-based, targeted therapies) and the shift toward MRD-guided consolidation (especially pre- and post-allogeneic HCT).

Key Prognostic Impact of MRD in Relapsed AML (2025)

MRD Status & Time Point	Context	3–5 Year OS (post-relapse)	Key Evidence (2024–2025)
MRD-negative (<0.01–0.03%) before allo-HCT in CR2	Any relapse	45–65%	EBMT 2024, CIBMTR 2025, ELN 2024
MRD-positive before allo-HCT in CR2	Despite intensive or low-intensity salvage	15–30%	Same + HOVON/SAKK data
MRD-negative after venetoclax + HMA/LDAC	First salvage	~50–60% (if consolidated)	Viale-A long-term, real-world registries

MRD Status & Time Point	Context	3–5 Year OS (post-relapse)	Key Evidence (2024–2025)
MRD-negative after intensive re-induction (FLAG-Ida, MEC, etc.)	First salvage, fit patients	40–55%	UK MRC/NCRI, GIMEMA
Persistent MRD+ after two cycles of salvage	Any regimen	<20% long-term survival	Multiple prospective trials

Recommended MRD Techniques in Relapsed AML (ELN 2024 / ICC 2022)

Method	Sensitivity	Applicability in Relapse	Preferred Use in Relapse Setting
Multicolor Flow Cytometry (MFC)	10^{-3} to 10^{-5}	~90–95% (LAIP or DfN approach)	Most widely used; fast turnaround
qPCR for fusion transcripts (e.g., PML::RARA, RUNX1::RUNX1T1, CBFB::MYH11)	10^{-4} to 10^{-6}	~25–30% of AML	Gold standard when applicable (especially CBF AML)
qPCR or ddPCR for NPM1 mut	10^{-5} to 10^{-6}	~30% of normal-karyotype AML	Highly prognostic in relapse
Next-Generation Sequencing (NGS)	10^{-3} (VAF 1–2%) standard; 10^{-6} possible with error-corrected panels	>98%	Increasingly preferred; detects clonal evolution & persistence of founder mutations (DNMT3A, TET2, ASXL1 often not informative)
Digital-droplet PCR (ddPCR)	10^{-5} to 10^{-6}	Targeted mutations (FLT3-ITD, IDH1/2, NPM1)	Excellent for monitoring specific targets post-targeted therapy

ELN 2024 consensus threshold for MRD negativity in AML:

- Flow: <0.1% (some centers use <0.01% with high-sensitivity protocols)
- Molecular (qPCR/ddPCR): <0.01% or undetectable with $\geq 10^{-4}$ sensitivity
- NGS: VAF <0.1–1% depending on mutation (persistent DTA mutations generally ignored)

MRD Testing Algorithm in Relapsed AML (ELN 2024 / NCCN 2025)

Time Point	Mandatory?	Preferred Method(s)	Clinical Decision if MRD+
At relapse (morphologic CR not yet achieved)	Yes	Flow + molecular (if target known)	Guides intensity of salvage
After 1–2 cycles of salvage therapy	Yes	Flow + NGS/qPCR	If MRD+ → switch regimen or add targeted agent

Time Point	Mandatory?	Preferred Method(s)	Clinical Decision if MRD+
Before proceeding to allo-HCT in CR2/CRi2	Mandatory	NGS + flow (both recommended)	If MRD+ and fit → additional therapy to achieve MRD-neg before HCT
Day +28–60 post-allo-HCT	Recommended (high-risk patients)	NGS or ddPCR	Pre-emptive azacitidine ± venetoclax, DLI, or clinical trial

Current Salvage Regimens & MRD Response Rates (2025)

Regimen	Patient Group	MRD-Negativity Rate	Notes
Venetoclax + HMA (aza/decitabine)	Unfit or older	40–60%	Highest MRD-neg rates in NPM1/IDH mutated
Venetoclax + LDAC	Unfit	30–50%	-
FLAG-Ida ± venetoclax or GO	Fit, <65–70 y	50–70%	Best in CBF AML
CPX-351 (liposomal dauno+cytarabine)	Secondary/tAML	~50%	-
Gilteritinib (FLT3 mutated)	FLT3+	30–50%	Deeper responses with combination
Ivosidenib/Enasidenib	IDH1/2 mutated	30–40%	-
Menin inhibitors (revumenib, ziftomenib)	NPM1-mut or KMT2A-r (trials)	50–70% (early data)	Emerging as preferred for these subtypes

Practical Take-Home Points for Clinicians (November 2025)

1. **Never transplant an MRD-positive relapsed AML patient without attempting further debulking** if the patient can tolerate it — the survival difference is ~30–40%.
2. **Use both flow and a molecular method** (NGS or targeted PCR) pre-HCT; NGS is increasingly required because relapse is frequently driven by clonal evolution not detected by original LAIP.
3. Persistent founder/clonal hematopoiesis mutations (DNMT3A, TET2, ASXL1) at relapse should **not** be used as the sole MRD marker.
4. In NPM1-mutated or core-binding factor AML, molecular MRD (qPCR/ddPCR) is far more sensitive and prognostic than flow.
5. Achieving MRD negativity (especially <0.01%) before HCT is now the strongest predictor of long-term survival after relapse, surpassing age, cytogenetics, or prior lines of therapy in multivariate models.

MRD has transformed relapsed AML from a nearly uniformly fatal disease (historical 5-year OS <10%) to one where 40–60% long-term survival is achievable in selected patients who attain deep MRD-negative responses before consolidation with allogeneic transplantation.